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Purpose of the study
To estimate the short-term probability of HAART
change and to evaluate factors associated with treatment
modification during the first year of contemporary
HAART.
Methods
We evaluated by logistic regression and Cox proportional
model analysis factors associated to treatment modifica-
tion during the first year of HAART in antiretroviral naïve
patients from a single HIV unit in Madrid. Variables
included in the analysis were: Basic sociodemographic
characteristics, data on the clinical course, VHC coinfec-
tion, antiretroviral therapy and immunologic and virologic
variables.
Results
From Jan/06 to Dec/09, 301 patients started HAART
(mean age 38.6, 75.4% male). Median CD4: 246, mean
viral load: 4.67 logs, 22.3% HCV coinfected. Patients
started HAART including TDF/FTC (84.7%), ABC/3TC
(8.3%), AZT/3TC (7%), EFV (53.5%), NVP (7.7%), LPV/r
(23.6%), DRV/r (2.0%) ATV/r (2.7%), FPV/r (6.3%), SQV/
r (0.5) and RAL (3.7%). One-year probability of HAART
modification was 0.26 (95%CI 0.21-0.26). Reasons for
HAART modification were toxicity (11%), simplification
(10.6%, including 8.31% of patients who switched from
TDF/FTC+EFV to TDF/FTC/EFV), Lack of efficacy
(1.3%) and other (i.e. poor adherence, pregnancy termina-
tion 3.3%). Most common toxicities leading to HAART
modification were skin rash (3.32%), CNS adverse events
(1.66%), gastrointestinal (1.33%) lipoatrophy (1.66%),
renal (1%), and osteopenia (1%). Patients who modified
HAART were less likely to achieve 1 year viral load sup-
pression than patients who didn’t change HAART (83.5%
vs 94.6%, p = 0.02) with no differences in CD4 cell recov-
ery. Multivariant logistic regression analysis showed that
a prior AIDS-defining condition [OR 1.90 (1.07-3.37)]
and AZT/3TC as nucleoside backbone [4.81 (1.88-12.3)]
were significantly associated to HAART modification.
A sensitivity analysis excluding TDF/FTC+EFV to TDF/
FTC/EFV switches showed two additional factors asso-
ciated to treatment modification: female sex [2.62 (1.30-
5.27)] and time since HIV diagnosis.
Conclusions
Treatment modification is still common during the first
year of HAART occurring in one quarter of patients.
While lack of efficacy of HAART is an uncommon rea-
son for change, toxicity and treatment simplification
remain important reasons for change. Women, patients
with a prior AIDS diagnosis and patients receiving AZT/
3TC as a backbone were more likely to change therapy.
Author details
1Hospital La Paz/Autónoma University School of Medicine. IdiPAZ, Internal
Medicine, Madrid, Spain.
2Hospital La Paz/Autónoma University School of
Medicine. IdiPAZ, HIV Unit, Madrid, Spain.
3Hospital La Paz/Autónoma
University School of Medicine. IdiPAZ, Biostatistical Unit, Madrid, Spain.
4Hospital La Paz/Autónoma University School of Medicine. IdiPAZ, Infectious
Diseases Unit, Madrid, Spain.
5Hospital La Paz/Autónoma University School of
Medicine. IdiPAZ, Madrid, Spain.
Published: 8 November 2010
doi:10.1186/1758-2652-13-S4-P15
Cite this article as: Martin et al.: Factors associated with treatment
modification during the first year of contemporary HAART. Journal of the
International AIDS Society 2010 13(Suppl 4):P15. 2Hospital La Paz/Autónoma University School of Medicine. IdiPAZ, HIV Unit,
Madrid, Spain
Full list of author information is available at the end of the article
Martin et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P15
http://www.jiasociety.org/content/13/S4/P15
© 2010 Perez-Valero et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.